NLBS — Nutralife Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.02m
- $2.14m
- $0.63m
Annual income statement for Nutralife Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.79 | 3.71 | 2.13 | 1.26 | 0.627 |
| Cost of Revenue | |||||
| Gross Profit | 0.735 | 1.5 | 0.598 | 0.51 | 0.084 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22.1 | 5.64 | 5.53 | 3.23 | 4.61 |
| Operating Profit | -20.3 | -1.92 | -3.4 | -1.97 | -3.98 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.6 | -2.07 | -4.01 | -2.89 | -5.83 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23.6 | -2.07 | -4.01 | -2.89 | -5.83 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.6 | -2.07 | -4.01 | -2.89 | -5.83 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.6 | -2.07 | -4.01 | -2.89 | -5.83 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.329 | -0.024 | -0.035 | -0.02 | -0.038 |